Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$121.43M$121.43M+22.6% vs Q3 2019 Net Income-$196.50M-$196.50MN/M vs Q3 2019 EPS Diluted-$2.50-$2.50N/M vs Q3 2019 Operating Income-$137,068,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$263,489,000N/M Margins · derivedOperating margin-112.9%+11.9 pt vs Q3 2019
Net margin-161.8%−34.3 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end